儿童肝脾T细胞淋巴瘤2例并文献复习

doi:10.12372/jcp.2025.24e1059

摘要/Abstract

摘要：

目的探讨肝脾γδT细胞淋巴瘤（HSγδTCL）患儿的临床特征、治疗及预后。方法回顾性收集2012年10月至2023年5月我院肿瘤科收治的2例HSγδTCL患儿的临床资料，并检索相关文献进行文献复习。结果 2例患儿分别为9、11岁男童，以脾大及血细胞减少起病，病理类型均为HSγδTCL。例1在诊断后给予化学治疗，因病情进展死亡。例2经过7个疗程的化学治疗及联合组蛋白去乙酰化酶抑制剂治疗，缓解后行异基因造血干细胞移植，目前存活。共检索到中英文报道的30例患儿，其中8例既往有慢性免疫性疾病病史，并接受过免疫抑制剂治疗；11例接受高强度的化疗联合造血干细胞移植，5例接受脾脏切除术及化疗；22例患儿死亡，诊断后中位生存时间短于1年。结论本病治疗效果差，化疗联合造血干细胞移植是可选择的治疗方法。

关键词: 肝脾γδT细胞淋巴瘤, 儿童, 化疗, 造血干细胞移植

Abstract:

Objective To investigate the clinical characteristics, treatment outcomes, and prognosis of hepatosplenic γδ T-cell lymphoma (HSγδTCL) in pediatric patients. Methods The clinical data of two pediatric patients with HS γδ TCL admitted to the oncology department of our hospital from October 2012 to May 2023 were retrospectively analyzed. Additionally, relevant literature was systematically searched and reviewed. Results The two patients were 9- and 11-year-old boys who presented with splenomegaly and cytopenia. Both were diagnosed with HSγδTCL. Patient 1 received chemotherapy but succumbed to disease progression. Patient 2 underwent seven cycles of chemotherapy in combination with histone deacetylase inhibitor therapy. After achieving remission, the patient received allogeneic hematopoietic stem cell transplantation and remains alive to date. A total of 30 pediatric cases were reviewed from the literature. Eight patients had a history of chronic immunodeficiency diseases and had received immunosuppressive therapy. Eleven patients underwent intensive chemotherapy combined with stem cell transplantation, while five patients had splenectomy followed by chemotherapy. Overall, 22 patients died, with a median survival time of less than one year after diagnosis. Conclusion HSγδTCL in children has a poor treatment outcome. Chemotherapy combined with hematopoietic stem cell transplantation is an alternative treatment strategy worthy of consideration.

Key words: hepatosplenic γδ T-cell lymphoma, child, chemotherapy, hematopoietic stem cell transplantation

中图分类号:

汪洁, 吴彬, 张兰男, 陈开澜. 儿童肝脾T细胞淋巴瘤2例并文献复习[J]. 临床儿科杂志, 2025, 43(9): 698-704.

WANG Jie, WU Bin, ZHANG Lannan, CHEN Kailan. Two cases of pediatric hepatosplenic T-cell lymphoma and literature review[J]. Journal of Clinical Pediatrics, 2025, 43(9): 698-704.

图/表 4

参考文献 41

[1]	Mellgren K, Attarbaschi A, Abla O. Non-anaplastic peripheral T cell lymphoma in children and adolescents—an international review of 143 cases[J]. Ann Hematol, 2016, 95(8): 1295-1305. doi: 10.1007/s00277-016-2722-y pmid: 27270301
[2]	Ferreri AJ, Govi S, Pileri SA. Hepatosplenic gamma-delta T-cell lymphoma[J]. Crit Rev Oncol Hematol, 2012, 83: 283-292. doi: 10.1016/j.critrevonc.2011.10.001 pmid: 22047938
[3]	Pro B, Allen P, Behdad A. Hepatosplenic T cell lymphoma: a rare but challenging entity[J]. Blood, 2020, 136(18): 2018-2026.
[4]	Horwitz SM, Ansell S, Ai WZ, et al. NCCN guidelines insights: T-cell lymphomas,version 1[J]. Natl Compr Canc Netw, 2020, 18(11): 1460-1467.
[5]	Rosolen A, Perkins SL, Pinkerton CR, et al. Revised international pediatric non-hodgkin lymphoma staging system[J]. J Clin Oncol, 2015, 33(18): 2112-2118. doi: 10.1200/JCO.2014.59.7203 pmid: 25940716
[6]	Takaya H, Masayoshi Y, Yoko M. Successful treatment of hepatosplenic T-cell lymphoma with fludarabine, high-dose cytarabine and subsequent unrelated umbilical cord bloor transplantation[J]. Int J Hematol, 2022, 115(1): 140-145.
[7]	Julio FF, Leila R, Helena U. Integrative genomic and transcriptomic analysis indentified candidate genes implicated in the pathogenesis of hepatosplenic T-cell lymphoma[J]. PLoS One, 2014, 9(7): e102977.
[8]	MD Kraus, DF Crawford, Z Kaleem. T gamma/delta hepatosplenic lymphoma in a hearttransplant patient after an Epstein-Barr virus positive lymphoproliferative disorder: a case report[J]. Cancer, 1998, 82(5) :983-92. pmid: 9486591
[9]	Chin M, Mugisima H, Takamura M. Hemophagocytic syndrome and hepatosplenic gammadelta T-cell lymphoma with isochromosome 7q and 8 trisomy[J]. J Pediatr Hematol Oncol, 2004, 26(6): 375-378. pmid: 15167351
[10]	Shale M, Kanfer E, Panaccione R. Hepatosplenic T cell lymphoma in inflammatory bowel disease[J]. Gut, 2008, 57: 1639-1641. doi: 10.1136/gut.2008.163279 pmid: 18667489
[11]	Al Mahmoud R, Weitzman S, Schechter T. Peripheral T-cell lymphoma in children and adolescents: a single-institution experience[J]. J Pediatr Hematol Oncol, 2012, 34: 611-616. doi: 10.1097/MPH.0b013e3182707592 pmid: 23042011
[12]	Shetty S, Mansoor A, Roland B. Ring chromosome 7 with amplification of 7q sequences in a pediatric case of hepatosplenic T-cell lymphoma[J]. Cancer Genet Cytogenet, 2006, 16(7): 161-163.
[13]	Lu CL, Tang Y, Yang QP. Hepatosplenic T-cell lymphoma: clinicopathologic, immunophenotypic, and molecular characterization of 17 Chinese cases[J]. Hum Pathol, 2011, 42(12): 1965-1978.
[14]	Mutreja D, Kotru M, Aggarwal M, et al. Hepatosplenic gamma delta T-cell lymphoma in a boy with visceral leishmaniasis: a case report[J]. J Med Case Rep, 2013, 7: 269.
[15]	Mackey AC, Green L, Liang LC. Hepatosplenic T cell lymphoma associated with infliximab use in young patients treated for inflammatory bowel disease[J]. J Pediatr Gastroenterol Nutr, 2007, 44(2): 265-267.
[16]	Patkar N, Nair S, Alex AA. Clinicopathological features of hepatosplenic T cell lymphoma: a single centre experience from India[J]. Leuk Lymphoma, 2012, 53(4): 609-615.
[17]	Rossbach HC, Chamizo W, Dumont DP. Hepatosplenic gamma/delta T-cell lymphoma with isochromosome 7q, translocation t(7;21), and tetrasomy 8 in a 9-year-old girl[J]. J Pediatr Hematol Oncol, 2002, 24(2): 154-157.
[18]	Belhadj K, Reyes F, Farcet JP, et al. Hepatosplenic gammadelta Tcell lymphoma is a rare clinicopathologic entity with poor outcome:report on a series of 21 patients[J]. Blood, 2003, 102(13): 4261-4269. doi: 10.1182/blood-2003-05-1675 pmid: 12907441
[19]	Domm JA, Thompson M, Kuttesch JF, et al. Allogeneic bone marrow transplantation for chemotherapy-refractory hepatosplenic gammadelta T-cell lymphoma: case report and review of the literature[J]. J Pediatr Hematol Oncol, 2005, 27(11): 607-610. pmid: 16282893
[20]	Voss MH, Lunning MA, Maragulia JC, et al. Intensive induction chemotherapy followed by early high-dose therapy and hematopoietic stem cell transplantation results in improved outcome for patients with hepatosplenic T-cell lymphoma: a single institution experience[J]. Clin Lymphoma Myeloma Leuk, 2013, 13(1): 8-14. doi: 10.1016/j.clml.2012.09.002 pmid: 23107915
[21]	Edwards J, Simmons E, Cordero S, et al. Retinal hemorrhages as a presenting sign in an adolescent patient with hepatosplenic gamma-delta T-cell lymphoma[J]. Pediatr Blood Cancer, 2010, 55(1): 190-192. doi: 10.1002/pbc.22485 pmid: 20486185
[22]	Sheila S, Jawhar R, Jennifer L, et al. Hepatosplenic γδ T-cell lymphoma of two adolescents: case report and retrospective literature review in children,adolescents, and young adults[J]. Pediatr Transplant, 2018, 22(5): e13213.
[23]	Yana P, Amy S, Amanda L, et al. Targeting EZH2 for the treatment of hepatosplenic T-cell lymphoma[J]. Blood Adv, 2020, 4(7): 1265-1269. doi: 10.1182/bloodadvances.2019001256 pmid: 32232478
[24]	Florian B, Philomena A, Till K, et al. Two cases of hepatosplenic T-cell lymphoma in adolescents treated for autoimmune hepatitis[J]. Pediatrics, 2016, 138(3): e20154245.
[25]	Nihull JS, Bernard H, Helena L, et al. Capillaritis as a skin manifestation of hepatosplenic gamma-delta T-cell lymphoma[J]. J Pediatr Hematol Oncol, 2022, 44(3): e733-e735.
[26]	竺晓凡, 邹尧, 陈玉梅, 等. 儿童肝脾γδT细胞淋巴瘤一例报告伴文献复习[J]. 中华血液学杂志, 2013, 11(24) : 613-615.
	Zhu XF, Zou Y, Chen YM, et al. A case of pediatric hepatosplenic γδT-cell lymphoma and literature review[J]. Zhonghua Xueyexue Zazhi, 2013, 11 (24) : 613-615.
[27]	Dhir A, Hill B, Waite ES. Pralatrexate-based therapy induced response in anadolescent with refractory hepatosplenic T-cell lymphoma[J]. Pediatr Blood Cancer, 2020, 67(11): e28460.
[28]	Falchook GS, Vega F, Dang NH, et al. Hepatosplenic gamma-delta T-cell lymphoma:clinipathological features and treatment[J]. Ann oncol, 2009, 20(6): 1080-1085. doi: 10.1093/annonc/mdn751 pmid: 19237479
[29]	Travert M, Huang Y, de Leval L, et al. Molecular features of hepatosplenic T-cell lymphoma unravels potential novel therapeutic targets[J]. Blood, 2012, 119: 5795-5806. doi: 10.1182/blood-2011-12-396150 pmid: 22510872
[30]	Yabe M, Medeiros LJ, Tang G, et al. Prognostic factors of hepatosplenic T-cell lymphoma: clinicopathologic study of 28 cases[J]. Am J Surg Pathol, 2016, 40(5): 676-688. doi: 10.1097/PAS.0000000000000614 pmid: 26872013
[31]	Chanan-Khan A, Islam T, Alam A, et al. Long-term survival with allogeneic stemcell transplant and donor lymphocyte infusion following salvage therapy with anti-CD52 monoclonal antibody (campath) in a patient with α/β hepatosplenicT-cell non-hodgkin's lymphoma[J]. Leuk Lymphoma, 2004, 45(8):1673-1675.
[32]	Tanase A, Schmitz N, Stein H, et al. Allogeneic and autologous stem cell transplantation for hepatosplenic T-cell lymphoma: a retrospective study of the EBMT Lymphoma Working Party[J]. Leukemia, 2015, 29(3): 686-688. doi: 10.1038/leu.2014.280 pmid: 25234166
[33]	Bojanini L, Jiang L, Tun AJ, et al. Outcomes of hepatosplenic T-cell lymphoma: the mayo clinic experience[J]. Clin Lymphoma Myeloma Leuk, 2021, 21(2): 106-112. doi: 10.1016/j.clml.2020.09.013 pmid: 33160933
[34]	中国临床肿瘤学会(CSCO)淋巴瘤专家委员会. 西达本胺不良反应管理中国专家共识[J]. 白血病·淋巴瘤, 2021, 30(9): 518-523.
	Lymphoma Expert Committee of Chinese Society of Clinical Oncology. Chinese expert consensus on adverse reaction management of chidamide[J]. Baixuebing·Linbaliu, 2021, 30(9): 518-523.
[35]	Liu W, Zhao D, Liu T, et al. A multi-centre, real-world study of chidamide for patients with relapsed or refractory peripheral T-cell lymphomas in China[J]. Front Oncol, 2021, 11: 750323-750327.
[36]	Zhang W, Su L, Liu L, et al. The combination of chidamide with the CHOEP regimen in previously untreated patients with peripheral T-cell lymphoma, a prospective,multicenter, single arm, phase Ib/2study[J]. Cancer Biol Med, 2021, 18(3): 841-848.
[37]	Waldmann TA, Chen Jing. Disorders of the JAK/STAT pathway in T cell lymphoma pathogenesis: implications for immunotherapy[J]. Annu Rev Immunol, 2017, 35: 533-550. doi: 10.1146/annurev-immunol-110416-120628 pmid: 28182501
[38]	McKinney M, Moffitt AB, Gaulard P, et al. The genetic basis of hepatosplenic T-celllymphoma[J]. Cancer Discov, 2017, 7: 369-379. doi: 10.1158/2159-8290.CD-16-0330 pmid: 28122867
[39]	Feldman AL, Sun DX, Law ME, et al. Overexpression of Syk tyrosine kinase in peripheral T-cell lymphomas[J]. Leukemia, 2008, 22(6): 1139-1143. doi: 10.1038/leu.2008.77 pmid: 18401419
[40]	Friedberg JW, Sharman J, Sweetenham J, et al. Inhibition of Syk with fostamatinib disodium has significant clinical activity in non Hodgkin lymphoma and chronic lymphocytic leukemia[J]. Blood, 2010, 115: 2578-2585. doi: 10.1182/blood-2009-08-236471 pmid: 19965662
[41]	Waldmann TA. JAK/STAT pathway directed therapy of T-cell leukemia/lymphoma: inspired by functional and structural genomics[J]. Mol Cell Endocrinol, 2017, 451: 66-70. doi: S0303-7207(17)30106-5 pmid: 28214593